Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Laura M. Dember, MD
Healthcare Professional Professor
Perelman School of Medicine
University of Pennsylvania
Blockley Hall, Office 920
423 Guardian Drive
Philadelphia, Pennsylvania, United States
Laura M. Dember is a Professor of Medicine and Epidemiology at the University of Pennsylvania Perelman School of Medicine where she is a faculty member in the Renal-Electrolyte and Hypertension Division and a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. She received her medical degree from Yale University followed by residency in Internal medicine from University of Pennsylvania and fellowship in Nephrology from Brigham and Women’s Hospital. Dr. Dember is a member of the Penn multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis.
Dr. Dember conducts patient-oriented research including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She has particular interests in hemodialysis vascular access and interventions to improve clinical outcomes in end-stage renal disease. Her research is funded by the National Institutes of Health. Dr. Dember is Principal Investigator for the Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium which is conducting early phase clinical trials targeting ESRD-associated inflammation and cardiovascular disease, and she is the Principal Investigator for the “TiME Trial”, a large, pragmatic cluster-randomized clinical trial being conducted through the NIH Health Care Systems Research Collaboratory.
Representative Publications:
myBinderRelated Content
-
Amyloidosis: A Unifying Diagnosis for Nephrotic Syndrome and Congestive Cardiac FailureDiagnosing patients simply with heart fa...
-
Primary Bladder Amyloidosis as a Cause of HaematuriaWe report the case of a 46-year-old man ...
-
External Beam Radiation Therapy for Amyloidosis of the Urinary BladderAmyloidosis is a condition characterized...
-
Secondary, AA, AmyloidosisSecondary, AA, amyloidosis is a rare sys...
-
Amyloidosis: StatisticsBecause amyloidosis is rare, the diagnos...
-
Case Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
-
Successful Treatment With Tofacitinib for Renal Disorder due to Amyloid A Amyloidosis and Immunoglobulin A Nephropat...Amyloid A (AA) amyloidosis is a rare but...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
